MARKET

IDYA

IDYA

Ideaya Bioscienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.63
-0.18
-1.52%
After Hours: 11.63 0 0.00% 16:00 09/25 EDT
OPEN
11.69
PREV CLOSE
11.81
HIGH
11.86
LOW
11.20
VOLUME
105.97K
TURNOVER
--
52 WEEK HIGH
19.97
52 WEEK LOW
2.950
MARKET CAP
353.11M
P/E (TTM)
-5.1462
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 2d ago
Ideaya and Pfizer to test doublet therapy in certain solid tumors
IDEAYA Biosciences (IDYA) expands its clinical trial collaboration and supply agreement with Pfizer (PFE) with a new study evaluating the combination of IDE196, a protein kinase inhibitor, and crizotinib, a
Seekingalpha · 2d ago
IDEAYA to evaluate IDE196+Pfizer's crizotinib combo in solid tumors harboring GNAQ/11 mutations
IDEAYA Biosciences (IDYA) has expanded its previous trial collaboration and supply agreement with Pfizer for the evaluation of the former's sponsored combination study of IDE196, a Protein Kinase C inhibitor, and
Seekingalpha · 2d ago
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced that it has expanded its clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) for an IDEAYA
PR Newswire · 2d ago
Billionaire Ken Griffin Snaps Up These 3 “Strong Buy” Stocks
TipRanks · 09/04 16:52
LD Micro 360 Companies --Set to Present this Week.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 09/02 22:21
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that management will present at the following upcoming investor relations events.
PR Newswire · 08/31 11:00
What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares?
Simply Wall St. · 08/19 18:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDYA. Analyze the recent business situations of Ideaya Bioscienc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDYA stock price target is 24.63 with a high estimate of 28.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 76
Institutional Holdings: 17.72M
% Owned: 58.36%
Shares Outstanding: 30.36M
TypeInstitutionsShares
Increased
17
5.53M
New
43
2.11M
Decreased
3
93.11K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Timothy Shannon
President/Chief Executive Officer/Director
Yujiro Hata
Chief Financial Officer
Paul Stone
Senior Vice President/Chief Scientific Officer
Michael Dillon
Senior Vice President
Mark Lackner
Vice President - Finance
Andres Briseno
Vice President/General Counsel/Secretary
Jason Throne
Vice President/Director of Human Resources
Julie Patel
Vice President
Paul Barsanti
Vice President
Mick O'Quigley
Independent Director
Garret Hampton
Independent Director
Scott Morrison
Independent Director
Terry Rosen
Independent Director
Thilo Schroeder
Independent Director
Jeffrey Stein
Independent Director
Wendy Yarno
Independent Director
Tim Shannon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IDYA
IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and WRN, in high microsatellite instability tumors (MSI) tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ideaya Biosciences Inc stock information, including NASDAQ:IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.